Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexpramipexole in eosinophilic asthma (EXHALE-1)
NCT04046939Phase 2Completed
- Sponsor
- Knopp Biosciences
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexpramipexole in eosinophilic asthma (EA) (4 arms), sponsored by Knopp Biosciences. Primary endpoint: Change in Blood Absolute Eosinophil Count at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04046939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046939.